Doxazosin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Doxazosin: From Hypertension/BPH to Migraine Disorder
One-Sentence Summary
Doxazosin is a selective alpha-1 adrenergic receptor antagonist primarily used for the treatment of hypertension and benign prostatic hyperplasia (BPH). The TxGNN model predicts it may be effective for Migraine Disorder, with 0 clinical trials and 1 publication currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension; Benign Prostatic Hyperplasia (BPH) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.20% |
| Evidence Level | L4 |
| Singapore Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why Is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacological information, Doxazosin is a selective alpha-1 adrenergic receptor antagonist. It blocks alpha-1 receptors on vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance — the basis of its antihypertensive and prostate-relaxing effects.
The mechanistic link to migraine rests on the fact that alpha-1 adrenergic receptors are widely distributed in cerebrovascular smooth muscle. Blocking these receptors can reduce cerebrovascular tone and theoretically inhibit the vasospasm associated with migraine attacks. Additionally, sympathetic nervous system overactivation is thought to contribute to migraine triggering, and Doxazosin may theoretically reduce this sympathetic drive as a prophylactic mechanism.
That said, the biological plausibility remains theoretical and indirect. The only available evidence (a 1997 Review/Commentary) describes informal clinical observations rather than controlled data. Furthermore, the drug is not registered in Singapore, adding a practical barrier to immediate clinical application. The prediction score is high, but the evidence base is thin.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9074296 | 1997 | Review/Commentary | Headache | Author's personal experience placing 10 migraine patients on terazosin or doxazosin. Decreased migraine frequency and/or severity was seen in 9 of 10 patients. However, 5 patients discontinued due to side effects. No serious adverse reactions were reported. No control group. |
Singapore Market Information
Doxazosin currently has no product registrations in Singapore. No licensed products are on file.
Safety Considerations
Please refer to the package insert for safety information.
Note: Safety data (key warnings, contraindications, and drug interactions) could not be retrieved in this evidence pack. Clinically, alpha-1 blockers as a class are associated with orthostatic hypotension (particularly as a first-dose effect), dizziness, and reflex tachycardia. These are especially relevant in the migraine patient population, where these side effects may overlap with or worsen migraine symptoms. The 1997 publication reported a 50% discontinuation rate due to side effects, reinforcing the need for a formal tolerability assessment.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence base for Doxazosin in migraine disorder consists of a single 1997 Review/Commentary reporting personal clinical observations in 10 uncontrolled patients. With no registered clinical trials, no Singapore marketing authorisation, and an L4 evidence level, there is insufficient foundation to move toward clinical adoption at this time.
To proceed, the following is needed:
- MOA documentation: Retrieve full mechanism of action from DrugBank API to strengthen the biological rationale
- Safety profile: Obtain Singapore-applicable prescribing information (warnings, contraindications, DDI data) before any safety screening can be completed
- Tolerability data in migraine population: The sole available publication reported a 50% dropout due to side effects — a dedicated tolerability study is a prerequisite
- Prospective clinical evidence: At minimum, a small prospective observational study or pilot RCT evaluating Doxazosin as migraine prophylaxis is needed before this candidate can advance to a Go/Proceed decision
- Comparison with established alpha-1 blockers: Evaluate how Doxazosin compares to other drugs in its class (e.g., prazosin, terazosin) which have slightly more literature coverage in headache disorders
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.